Stock Movers: Cooper, Freeport-McMoRan, Oracle (Podcast)

Cooper shares fell as much as 20%, their largest intraday decline since 2008, after the healthcare-supplies company cut full-year adjusted EPS and revenue guidance amid CooperVision weakness. Freeport-McMoRan declined as the White House has yet to decide on copper tariffs. Oracle is under pressure ahead of earnings over its AI infrastructure debt and spending, with quarterly capex expected near $20 billion and free cash flow projected at roughly negative $10 billion.

Analysis

ORCL is becoming a duration-and-credit trade rather than a pure AI beneficiary. If management cannot demonstrate that incremental cloud/AI bookings convert into committed, margin-accretive revenue faster than depreciation, interest expense, and lease obligations rise, the equity multiple can compress even with strong top-line growth. The key near-term read-through is to AI infrastructure peers: a weak cash-flow defense would pressure highly levered or capex-intensive beneficiaries such as CRWV and selected data-center REITs, while favoring asset-light software vendors with AI monetization but materially lower capital intensity, including MSFT and NOW.

The market may be underpricing the financing constraint: elevated capex is manageable only while debt markets remain receptive and customer contract duration is sufficiently long to support project-level underwriting. Over the next 1-3 months, focus on ORCL's booked backlog quality, remaining performance obligations, capex guidance, financing needs, and any evidence that hyperscaler competition is forcing lower cloud pricing. The bearish thesis is falsified if management shows accelerating cloud gross margin, backlog conversion that exceeds capex growth, and credible free-cash-flow normalization within the next fiscal year.

FCX's tariff exposure is less a directional copper call than a regional-basis and policy-timing problem. A restrictive US tariff regime could lift domestic copper realizations and benefit US-centric scrap, recycling, and secondary-processing capacity, but it risks demand destruction among US wire, grid, and manufacturing customers and could redirect imported units into non-US markets. Until policy details clarify product scope, exemptions, and implementation dates, copper-equity volatility should exceed underlying copper volatility; this argues for relative-value positioning rather than an outright FCX short.

COO's reset creates a more specific medical-device watch item: softness in vision care can reflect channel inventory normalization, pricing pressure, or slower consumer replacement behavior rather than a permanent category contraction. If peers such as ALC and JNJ do not corroborate weakened optical demand over the next reporting cycle, COO's drawdown could become a tactical mean-reversion opportunity; if they do, consensus estimates across elective and recurring eye-care exposure likely remain too high for 6-12 months.

Key Decisions for Investors

• Maintain an underweight ORCL into earnings or express via a 1-3 month put spread; target a 10-15% downside if capex or financing guidance rises without a proportional increase in contracted cloud backlog. Cover if management provides a credible path to positive free cash flow within the next fiscal year and cloud-margin expansion.
• Pair long MSFT / short ORCL over the next 1-3 months: both retain AI demand exposure, but MSFT has a stronger balance sheet and diversified cash generation. The pair is at risk if Oracle reports materially stronger OCI backlog conversion or a major long-duration customer commitment.
• Avoid outright FCX directional exposure until tariff details are published; instead, monitor the FCX-to-HG copper beta and initiate a tactical long FCX only if policy raises US realized-price economics without evidence of downstream demand erosion. A broad tariff exemption or delayed implementation would remove the near-term catalyst.
• Set an earnings-season alert on ALC and JNJ eye-care commentary. If neither reports comparable volume or pricing weakness, consider a small 3-6 month long COO position after estimate cuts stabilize; exit if CooperVision organic growth remains below revised guidance or management identifies sustained share loss.